The role of cancer stem cells in recurrent and drug-resistant lung cancer

Advances in Experimental Medicine and Biology

Volumn 890, Issue , 2016, Pages 57-74

  Suresh, Raagini ^a   Ali, Shadan ^a   Ahmad, Aamir ^b   Philip, Philip A ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

BR DIM; Cancer stem cells; CDF; Curcumin; Drug resistant; Lung cancer; MicroRNAs

Indexed keywords

ALDEHYDE DEHYDROGENASE; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CURCUMIN; CURCUMIN DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; LET 7 PROTEIN; MICRORNA; MICRORNA 200; MICRORNA 21; MICRORNA 212; MICRORNA 34A; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; TRANSCRIPTION FACTOR NANOG; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; DRUG RESISTANCE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CURCUMIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84951874607     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-24932-2_4     Document Type: Chapter

References (74)

1. Pathak AK, Bhutani M, Mohan A, Guleria R, Bal S, Kochupillai V (2004) Non small cell lung cancer (NSCLC): current status and future prospects. Indian J Chest Dis Allied Sci 46: 191-203.
2. Singh S, Chellappan S (2014) Lung cancer stem cells: molecular features and therapeutic targets. Mol Aspects Med 39: 50-60.
3. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH et al (2011) Difluorinatedcurcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 28: 827-838.
4. Hu Y, Fu L (2012) Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res 2: 340-356.
5. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY et al (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3, e2637.
6. Wu Y, Wu PY (2009) CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 18: 1127-1134.
7. Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, Kikuchi E et al (2014) CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol 19: 254-259.
8. Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y et al (2012) Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer 77: 162-167.
9. Herpel E, Jensen K, Muley T, Warth A, Schnabel PA, Meister M et al (2011) The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer Res 31: 4491-4500.
10. Russo JE, Hilton J (1988) Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res 48: 2963-2968.
11. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B et al (2010) Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70: 9937-9948.
12. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH et al (2013) ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 328: 144-151.
13. Alamgeer M, Ganju V, Szczepny A, Russell PA, Prodanovic Z, Kumar B et al (2013) The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 68: 1095-1104.
14. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L et al (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106: 16281-16286.
15. Sung JM, Cho HJ, Yi H, Lee CH, Kim HS, Kim DK et al (2008) Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 371: 163-167.
16. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L et al (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3, e2428.
17. Li L, Yu H, Wang X, Zeng J, Li D, Lu J et al (2013) Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy. J Exp Clin Cancer Res 32: 28.
18. Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim NH et al (2012) Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41: 310-316.
19. Du Y, Ma C, Wang Z, Liu Z, Liu H, Wang T (2013) Nanog, a novel prognostic marker for lung cancer. Surg Oncol 22: 224-229.
20. Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26: 3008-3017.
21. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M et al (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99: 100-109.
22. Kim RJ, Park JR, Roh KJ, Choi AR, Kim SR, Kim PH et al (2013) High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2alpha. Cancer Lett 333: 18-31.
23. Stacy AE, Jansson PJ, Richardson DR (2013) Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol 84: 655-669.
24. Mimeault M, Hauke R, Batra SK (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83: 673-691.
25. Siu MK, Wong ES, Chan HY, Ngan HY, Chan KY, Cheung AN (2008) Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. Am J Pathol 173: 1165-1172.
26. Xiao D, He J (2010) Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2: 154-159.
27. Trumpp A, Wiestler OD (2008) Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat Clin Pract Oncol 5: 337-347.
28. Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC et al (2013) Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res 73: 406-416.
29. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L et al (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944-950.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al (2008) The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
31. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F et al (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-361.
32. Zhang Y, Wei J, Wang H, Xue X, An Y, Tang D et al (2012) Epithelial mesenchymal transition correlates with CD24+ CD44+ and CD133+ cells in pancreatic cancer. Oncol Rep 27: 1599-1605.
33. Giarnieri E, De VC, Noto A, Roscilli G, Salerno G, Mariotta S et al (2013) EMT markers in lung adenocarcinoma pleural effusion spheroid cells. J Cell Physiol 228: 1720-1726.
34. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.
35. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3654.
36. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S et al (2012) Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148: 259-272.
37. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T (2010) Epithelialmesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 30: 2513-2517.
38. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J et al (2010) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV nonsmall-cell lung cancer. Zhongguo Fei Ai Za Zhi 13: 171-189.
39. Kusumbe AP, Bapat SA (2009) Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69: 9245-9253.
40. Kim EY, Lee SS, Shin JH, Kim SH, Shin DH, Baek SY (2014) Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model. Clin Exp Med 14: 215-224.
41. Patel P, Chen EI (2012) Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne) 3: 125.
42. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
43. Mimeault M, Batra SK (2011) Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med 6: 31.
44. Liu C, Tang DG (2011) MicroRNA regulation of cancer stem cells. Cancer Res 71: 5950-5954.
45. Yu Y, Sarkar FH, Majumdar AP (2013) Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl Oncol 6: 180-186.
46. Sarkar FH, Li Y, Wang Z, Kong D, Ali S (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 13: 57-66.
47. Incoronato M, Garofalo M, Urso L, Romano G, Quintavalle C, Zanca C et al (2010) miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 70: 3638-3646.
48. Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I (2012) MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics 22: 198-205.
49. Rui W, Bing F, Hai-Zhu S, Wei D, Long-Bang C (2010) Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 14: 206-214.
50. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W et al (2011) Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 71: 3400-3409.
51. Ahmad A, Maitah MY, Ginnebaugh KR, Li Y, Bao B, Gadgeel SM et al (2013) Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol 6: 77.
52. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756.
53. Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M et al (2010) Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthasetargeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 9: 1647-1656.
54. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
55. Garofalo M, Croce CM (2013) MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat 16: 47-59.
56. Garofalo M, Romano G, Di LG, Nuovo G, Jeon YJ, Ngankeu A et al (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18: 74-82.
57. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE et al (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17: 1298-1307.
58. Basak SK, Veena MS, Oh S, Lai C, Vangala S, Elashoff D et al (2013) The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression. PLoS One 8, e73195.
59. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930.
60. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S et al (2011) Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 6, e17850.
61. Jiang M, Zhang P, Hu G, Xiao Z, Xu F, Zhong T et al (2013) Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients. Mol Cell Biochem 383: 67-75.
62. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K (2010) Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39: 761-772.
63. Dandawate P, Padhye S, Ahmad A, Sarkar FH (2013) Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv Transl Res 3: 165-182.
64. Soubani O, Ali AS, Logna F, Ali S, Philip PA, Sarkar FH (2012) Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis 33: 1563-1571.
65. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, Singh M (2009) Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res 15: 543-552.
66. Rahimi M, Huang KL, Tang CK (2010) 3, 3′-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. Cancer Lett 295: 59-68.
67. Xue L, Firestone GL, Bjeldanes LF (2005) DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24: 2343-2353.
68. Hsu EL, Chen N, Westbrook A, Wang F, Zhang R, Taylor RT et al (2008) CXCR4 and CXCL12 down-regulation: a novel mechanism for the chemoprotection of 3, 3′-diindolylmethane for breast and ovarian cancers. Cancer Lett 265: 113-123.
69. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG et al (2013) Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 32: 209-221.
70. Ye MX, Li Y, Yin H, Zhang J (2012) Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci 13: 3959-3978.
71. Zhang H, Yu T, Wen L, Wang H, Fei D, Jin C (2013) Curcumin enhances the effectiveness of cisplatin by suppressing CD133 cancer stem cells in laryngeal carcinoma treatment. Exp Ther Med 6: 1317-1321.
72. Mimeault M, Batra SK (2014) Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med 39: 3-32.
73. Zhang J, Zhang T, Ti X, Shi J, Wu C, Ren X et al (2010) Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem Biophys Res Commun 399: 1-6.
74. Zhang J, Du Y, Wu C, Ren X, Ti X, Shi J et al (2010) Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186 signaling pathway. Oncol Rep 24: 1217-1223.